Literature DB >> 16698092

Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy.

Joaquín Navarro1, Carol Aristimuño, Silvia Sánchez-Ramón, Dolores Vigil, Ma Luisa Martínez-Ginés, Eduardo Fernández-Cruz, Clara de Andrés.   

Abstract

Glucocorticoids remain the treatment of choice for MS relapses. However, little is known on the effect of intravenous methylprednisolone (IVMP) on dendritic cells (DCs) and regulatory T-cells (TReg). Our main goal was to quantify circulating myeloid and plasmacytoid DCs (mDCs and pDCs), and TReg at MS relapse versus healthy controls; and to analyse the short-term changes after IVMP for MS relapse. MS patients at relapse compared to controls showed higher %CD4+CD25high+ TReg (p<0.01). After 5-days of IVMP, activated T-lymphocytes (p=0.001), pDCs (p<0.0001), and CD11c+ mDCs (p<0.0001) decreased. By contrast, CD4+CD25+ and CD4+CD25high+ TReg further increased (p<0.0001 both). Changes on these subsets may play a relevant role in the immunosuppressive activity of this drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698092     DOI: 10.1016/j.jneuroim.2006.03.022

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

Review 1.  The effects of immunosuppression on regulatory CD4(+)CD25(+) T cells: impact on immunosuppression selection in transplantation.

Authors:  Aqeel Javeed; Yong Zhao
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 2.  The role of dendritic cells in CNS autoimmunity.

Authors:  Alla L Zozulya; Benjamin D Clarkson; Sonja Ortler; Zsuzsanna Fabry; Heinz Wiendl
Journal:  J Mol Med (Berl)       Date:  2010-03-09       Impact factor: 4.599

3.  Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.

Authors:  U Feger; C Luther; S Poeschel; A Melms; E Tolosa; H Wiendl
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

4.  Sex-hormone receptors pattern on regulatory T-cells: clinical implications for multiple sclerosis.

Authors:  Carol Aristimuño; Roseta Teijeiro; Lara Valor; Bárbara Alonso; Marta Tejera-Alhambra; Clara de Andrés; Desamparados Oliver Miñarro; Nieves López-Lazareno; Florence Faure; Silvia Sánchez-Ramón
Journal:  Clin Exp Med       Date:  2012-01-07       Impact factor: 3.984

5.  Sleep-dependent activity of T cells and regulatory T cells.

Authors:  T Bollinger; A Bollinger; L Skrum; S Dimitrov; T Lange; W Solbach
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

6.  The T-cell pool is anergized in patients with multiple sclerosis in remission.

Authors:  Moa E Fransson; Lina S E Liljenfeldt; Jan Fagius; Thomas H Tötterman; Angelica S I Loskog
Journal:  Immunology       Date:  2008-06-24       Impact factor: 7.397

7.  Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.

Authors:  C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

8.  Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis.

Authors:  L Xu; Z Xu; M Xu
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

9.  Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

Authors:  M Braitch; S Harikrishnan; R A Robins; C Nichols; A J Fahey; L Showe; C S Constantinescu
Journal:  Acta Neurol Scand       Date:  2009-04       Impact factor: 3.209

10.  Decreased 4-1BB expression on CD4+CD25 high regulatory T cells in peripheral blood of patients with multiple sclerosis.

Authors:  G-Z Liu; A C Gomes; L-B Fang; X-G Gao; P Hjelmstrom
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.